Abstract: A composition/formula for enhancing the grip of certain athletes and professionals to hold or otherwise “stick” onto an object like a piece of sports equipment, a tool handle or an exercise mat. The composition consists of: a magnesium carbonate base to which are added a natural gum rosin, isopropyl alcohol, hydroxyl ethyl cellulose (a plant-based thickener) and certain preferred essential oils (for fragrance and consistency). A limited quantity of candelilla wax may be blended therewith.

Abstract: To provide a water-soluble hyaluronic acid gel which does not contain a large amount of an organic solvent, wherein hyaluronic acid is not chemically modified. A water-soluble hyaluronic acid gel which contains hyaluronic acid, a polyhydric alcohol, an acid, and 0-10% by mass of a water-soluble organic solvent.

Abstract: The invention relates to formulations containing liquid ester quats and/or imidazolinium salts and polymer thickeners and to the use thereof.

Abstract: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, an emulsion containing at least an aqueous phase and an oily phase, the said oily phase comprising at least: (i) a compound consisting of up to 99.9% by weight of silicone elastomer(s) and from 0.1% to 10% by weight of surfactant(s), said surfactant(s) being chosen from polyoxyethers of C 10-C 18 fatty alcohols; (ii) a silicone elastomer powder coated with a silicone resin, and (iii) a filler which contains a polymer comprising at least the alkyl(meth)acrylate monomer, the silicone elastomer of compound (i) being different from the powder (ii).

Abstract: Disclosed is a shaving preparation imparting durable lubricity. The shaving preparation has one or more silicone polyethers and one or more water-soluble polymers that associate with the one or more silicone polyethers in aqueous solution. The lubricity of the shaving preparation can be reactivated by wetting the skin after shaving without applying an additional amount of the shaving preparation. Also disclosed is a method for using the shaving preparation.

Abstract: An aerosol antiperspirant composition comprising: at least one active antiperspirant ingredient, a bis-vinyl dimethicone/dimethicone copolymer, a silicone solvent, at least one fatty acid ester and at least one propellant.

Abstract: A nano freeze dry process of preparation for a cosmetic composition having a bioactive agent for providing an anti-aging effect on a skin, comprising the steps of: placing the cosmetic composition having a bioactive agent into a capsule container; and nano freeze drying the cosmetic composition by: freezing the cosmetic composition in the capsule container at ?170° C.; increasing the temperature to ?85° C. and allowing sublimation under vacuum condition; then increasing the temperature to 35° C.; and vacuum drying to obtain a final product, wherein a volume of the cosmetic composition remains unchanged after the process, a water content of less than 5% is inside the final, at least 80% of bioactivity of the cosmetic composition is retained, and significant anti-aging effect is observed after a two-day treatment.

Abstract: Compositions for improving the health and appearance of human hair, skin, and nails, and methods of using and preparing such compositions are disclosed.

Abstract: The present invention relates to a composition for stimulating hair growth or preventing hair loss, which contains a conditioned medium or extract of neural stem cells (NSCs) isolated from the ventricular zone of the human brain, and to a preparation method thereof. The conditioned medium or extract of neural stem cells according to the present invention contains various growth factors and cytokines, and thus has an excellent effect on the stimulation of hair growth.

Abstract: The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.

Abstract: The present invention generally relates to the transdermal delivery of fluticasone and other glucocorticoids. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment, for example, a high ionic strength environment. One set of embodiments provides a composition for transdermal delivery comprising fluticasone and/or a salt thereof, and optionally, a nitric oxide donor. Other glucocorticoids can also be used in some cases. Such compositions may be used to facilitate the delivery of effective amounts of fluticasone or other glucocorticoids systemically or to deeper tissues, rather than only locally or superficially, and in some cases, the effects of fluticasone or other glucocorticoids may be prolonged for unexpectedly long periods of time, e.g., days or weeks.

Abstract: The present invention provides topical pharmaceutical or cosmetic compositions comprising a pharmaceutical or cosmetic carrier comprising at least 3% by weight of phospholipid; at least 20% by weight of C2-C4 alcohol; at least 0.05% by weight keratolytic agent; and optionally, comprising up to 2% by weight of water; and pharmacologically or cosmetically active agent dissolved in said carrier. The compositions are sprayable. Also disclosed is a method of preparing the composition and use thereof, as well as the pharmaceutical or cosmetic carriers as such.

Abstract: The present invention relates to a stem cell composition for intravenous administration, which contains stem cells at a concentration of 1×107 to 5×108 cells/ml, in which the stem cells have a diameter of 10-20 ?m and are present as single cells. The stem cell composition according to the present invention is suitable for intravenous administration, and enables the stem cells to securely reach a target tissue after intravascular administration so as to exhibit their activity in the target tissue. Thus, it can significantly increase the therapeutic effects of the stem cells.

Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.

Abstract: An acicular body includes a support base, and a needle formed on the support base and containing a chitosan derivative.

Abstract: The present invention generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.

Abstract: The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material.

Abstract: Disclosed is an oral pharmaceutical composition for preventing or treating dry eye syndrome, which comprises rebamipide or a prodrug thereof, or a pharmaceutically acceptable salt thereof, as an active ingredient. The compounds can treat dry eye syndrome via oral route, and can be thus employed safely and conveniently compared to conventional eye drops.

Abstract: This invention relates to a method for treating a swallowing disorder in a patient suffering from aspiration before, during and/or after the swallowing reflex, and to a bolus for use in the treatment of a swallowing disorder in such a patient.

Abstract: This invention provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for delivery to the lung by inhalation. This invention also provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for the treatment of respiratory disease.

Abstract: The present invention relates to drug formulations in dry powder form for administration by inhalation and indicated for the treatment of obstructive airway syndromes such as asthma and chronic obstructive pulmonary disease (COPD).

Abstract: The administration of levoleucovorin is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salt of levoleucovorin has a limited solubility in water and forms almost insoluble degradation products. Therefore aqueous solutions are unstable and precipitates are resulting. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions containing calcium salts, magnesium or zinc salts of levoleucovorin and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt are disclosed.

Abstract: Provided are compositions and methods for producing water-soluble powders that contain additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including coenzyme Q10, and other oil-based additives.

Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Abstract: The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.

Abstract: A liposomal siRNA composition is described. The liposomes are formed of neutral liposome forming components, and the composition comprising additionally sugar. The composition provides reduced expression of target gene, without causing systemic toxicity. The composition is produced by a dehydration-rehydration technique to provide high yields and good control of liposome size.

Abstract: The invention relates to a new powder composition which comprises in admixture: lactic acid, lactose and kaolin, wherein the amount of lactic acid is such that the pH of the powder composition should be within the range of about 3 to 4. Said powder composition may be use as a veterinary drug and in treating and/or preventing a disorder in the auditory canal of dogs and cats.

Abstract: The invention provides for compositions comprising nanoparticles comprising a core, water-soluble polymer and an RGD peptide and a poloxamer.

Abstract: The invention relates to a process for stabilizing the drug release profile of a polymer film coated pharmaceutical composition, wherein the pharmaceutical composition comprises a core comprising an active pharmaceutical ingredient and a polymer film coating onto the core which was applied by a spray coating process, including a subsequent drying step, by applying microwave-irradiation, infrared-irradiation, UV-irradiation or ultra sonic wave irradiation to the polymer film coated pharmaceutical compositions.

Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.

Abstract: In one aspect, the present invention relates to a system for the modified release of one or more active ingredients, comprising a polymeric matrix based on hyaluronic acid with molecular weight ranging from 100 to 100,000 Daltons and a non-ionic polymer which jellifies in contact with water, in which one or more active ingredients are dispersed, optionally in form of microgranules or microcapsules.

Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Method of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

Abstract: The present invention relates to pharmaceutical tablets comprising amorphous compound I or pharmaceutically acceptable salts thereof, and an inert organic carrier.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products and compositions comprising acamprosate and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Described herein are oral pharmaceutical formulations comprising a core component and a coating composition applied on the core component. Also described is a process for producing said oral pharmaceutical formulations.

Abstract: Provided are heat-processed or heat-processible health food products beneficially affecting the consumer's intestinal microbial balance. The food products are particularly liquid-based products which comprise a probiotic component capable of resisting heat and humidity.

Abstract: Pharmaceutical composition with a controlled release of a metabolically active sugar, especially glucose, consisting of pellets containing a pellet core and a pellet core coating, the substance of which consists in that the pellet core contains at least 50% by weight of the metabolically active sugar, related to the total weight of the pellet core, at least one osmotically active substance or a disintegrant in a total amount up to 50% by weight, related to the total weight of the pellet core, and possibly standard excipients, wherein the pellet core coating consists of a polymeric membrane comprising a polymer of a cellulose derivative and/or methacrylate derivative, the weight of the pellet core coating being 5-50% by weight, related to the total weight of the pellet and the pharmaceutical composition contains pellets with at least one of the four different release profiles of the metabolically active sugar.

Abstract: The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

Abstract: Forming a coated core by using a fluidized bed processor that discharges a spray containing atomized air and a coating solution where the coating solution contains an active. Then, wetting the core with the coating solution and drying the wetted cores to form coated cores. These steps can be repeated until an appropriate amount of active has been applied. The coated cores are visually perceived as smooth under a microscope with a total magnification of 40×.

Abstract: Compositions for inhibiting oligonucleotide activity in vitro or in vivo to a cell that are formulated with at least one oligonucleotide encapsulated in a lipid nanoparticle, methods of making, and methods of using the same are disclosed.

Abstract: A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.

Abstract: A 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal and its use as an opioid antagonist are disclosed. The invention also relates to a drug-in-adhesive transdermal patch containing the analgesic fentanyl, a mu opioid agonist, or an analog thereof and a 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal, as an opioid antagonist. A transdermal patch of the invention is tamper-resistant and an abuse deterrent which protects against drug misuse or abuse. The invention also provides a method of treating pain, such as acute, chronic, or intermittent pain, by applying a drug-in-adhesive transdermal patch according to the invention to the skin of a patient in need thereof. Also disclosed is an improved transdermal patch for administering fentanyl or an analog thereof, or for administering a mu opioid agonist, the improvement wherein the transdermal patch contains a 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal in an abuse limiting amount.

Abstract: The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease.

Abstract: A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating.

Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.

Abstract: Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.

Abstract: The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a tall oil fatty acid for use in the prevention of growth of harmful bacteria in the animal digestive tractand/or in the prevention of intestinal disorders. The invention further relates to a feed supplement and a feed composition comprising tall oil fatty acid.

Abstract: The invention provides low concentration, stable compositions for the treatment of lesions associated with herpes viral infections. The compositions are in a form selected from creams and gels containing trichloroacetic acid in an amount of between 2.5% (m/m) and 6% (w/w) of the weight of the cream or gel.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.